ATR and small cell lung carcinoma: The cisplatin screen did not lead to the identification of any novel candidates but confirmed previously described targets ameliorating cisplatin response in SCLC (Supplementary Fig. S1A; Supplementary Table S1), including inhibitors of EZH2 and the canonical DNA damage regulators (e.g., CHK1/2 and ATR; refs. 21, 22).